hemoregulatory peptide 5b profile

hemoregulatory peptide 5b: synthetic analog of granulocyte chalone; initially identified in extracts of rodent bone marrow and human leukocytes; monomer inhibits both formation of GM-CFC colonies and cytotoxic drug induced recruitment of murine CRU-S cells into active cell cycle; dimer has stimulatory activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	123651
SCHEMBL ID	10341273
MeSH ID	M0121202

Synonym
pglu-glu-asp-cys-lys-oh
peedck
l-lysine, n2-(n-(n-(n-(5-oxo-l-prolyl)-l-alpha-glutamyl)-l-alpha-aspartyl)-l-cysteinyl)-
glp-glu-asp-cys-lys-oh
hemoregulatory peptide 5b
pyroglutamyl-glutamyl-aspartyl-cysteinyl-lysine
sp1 pentapeptide
hp 5b
84588-89-6
SCHEMBL10341273
(2s)-6-amino-2-[(2r)-2-[(2s)-3-carboxy-2-[(2s)-4-carboxy-2-{[(2s)-5-oxopyrrolidin-2-yl]formamido}butanamido]propanamido]-3-sulfanylpropanamido]hexanoic acid
pyroglu-glu-asp-cys-lys
pglu-glu-asp-cys-lys
((s)-5-oxopyrrolidine-2-carbonyl)-l-glutamyl-l-aspartyl-l-cysteinyl-l-lysine
n~2~-[2-({3-carboxy-2-[(4-carboxy-1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl)methylidene]amino}butylidene)amino]-1-hydroxypropylidene}amino)-1-hydroxy-3-sulfanylpropylidene]lysine
DTXSID701004874
(2s)-6-amino-2-[[(2r)-2-[[(2s)-3-carboxy-2-[[(2s)-4-carboxy-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]butanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]hexanoic acid

Excerpt	Reference	Relevance
" No adverse effects have been noted from continuous infusions of the peptide."	( Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice. Alisauskas, RM; Blumenthal, RD; Goldenberg, DM; Sharkey, RM, 1997)	0.3

Excerpt	Relevance	Reference
" increasing dose intensity, and 4) the possibility of using preclinical data to optimize the frequency of dosing in patient trials."	( Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression. Alisauskas, R; Blumenthal, RD; Goldenberg, DM; Lew, W; Sharkey, RM, 1998)	0.3

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	10 (23.26)	18.7374
1990's	28 (65.12)	18.2507
2000's	3 (6.98)	29.6817
2010's	2 (4.65)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	8 (18.60%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (81.40%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
amifostine anhydrous Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.	3.1	1	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	1.98	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
cytarabine [no description available]	4.33	6	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
pyrrolidonecarboxylic acid Pyrrolidonecarboxylic Acid: A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of GLUTAMINE or GLUTATHIONE metabolism.. 5-oxo-L-proline : An optically active form of 5-oxoproline having L-configuration.	7.9	43	5-oxoproline; L-proline derivative; non-proteinogenic L-alpha-amino acid	algal metabolite
deoxycytidine [no description available]	1.98	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
goralatide goralatide: from fetal calf bone marrow; exerts a high inhibitory activity on the proliferation of hematopoietic pluripotent stem cells. goralatide : A tetrapeptide that is Ser-Asp-Lys-Pro in which the N-terminal amino group carries an acetyl group. It is selective inhibitor of primitive haematopoietic cell proliferation and exhibits anti-inflammatory, anti-fibrotic, and pro-angiogenic properties.	5.76	7	oligopeptide; tetrapeptide	anti-inflammatory agent; pro-angiogenic agent
tamoxifen [no description available]	2.03	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
sk&f 107647 SK&F 107647: a synthetic hematoregulatory peptide that shares biological and/or modulatory activities with natural hematopoetic cytokines	1.98	1
ammonium trichloro(dioxoethylene-o,o'-)tellurate ammonium trichloro(dioxoethylene-O,O'-)tellurate: has potential therapeutic application; inhibits HIV-1 reverse transcriptase and replication	3.1	1
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	1.96	1
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	4.61	3
agar Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.	1.97	1

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	3.3	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.3	2
Granulocytic Leukemia, Chronic [description not available]	2.68	3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2.68	3
Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.	1.98	1
Benign Neoplasms, Brain [description not available]	1.98	1
Breast Cancer [description not available]	1.98	1
Astrocytoma, Grade IV [description not available]	1.98	1
Glial Cell Tumors [description not available]	1.98	1
Germinoblastoma [description not available]	2.39	2
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	1.98	1
Breast Neoplasms Tumors or cancer of the human BREAST.	1.98	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	1.98	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	1.98	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.39	2
Acute Lymphoid Leukemia [description not available]	1.99	1
Leucocythaemia [description not available]	2.39	2
Acute Myelogenous Leukemia [description not available]	2.38	2
Acute Disease Disease having a short and relatively severe course.	1.99	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.39	2
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.38	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	1.99	1
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	1.99	1
Leukocytopenia [description not available]	3.32	2
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	3.32	2
Anemia, Hypoplastic [description not available]	2.92	1
Thrombopenia [description not available]	2.92	1
Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.	2.92	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.92	1
Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	1.97	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	3.58	3
Experimental Neoplasms [description not available]	1.97	1

hemoregulatory peptide 5b

Description

Cross-References

Synonyms (17)

Research Excerpts

Toxicity

Dosage Studied

Research

Studies (43)

Study Types